These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-003892-35 A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allergoid Preparation of Ho... bad-data
Reported results 2005-000025-35 A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of bi... 2010-08-18 due-trials
Reported results 2006-000934-11 A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacacy of a specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation o... 2011-02-23 due-trials
Reported results 2006-005304-14 Design of optimally-diagnostic skin test solutions for diagnosis of sensitisation to a 6-grass pollen mixture, house dust mite (Dermatophagoides pteronyssinus), birch pollen and mugwort pollen and alt... 2008-07-01 due-trials
Reported results 2006-005911-82 A multicenter, placebo-controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children with... 2015-08-17 due-trials
Reported results 2007-000823-16 A multicenter, multinational, placebo-controlled, double-blind, randomized study to evaluate efficacy and safety of a perennial, sublingual specific immunotherapy in patielnts with rhinoconjunctivitis... 2011-10-20 due-trials
Reported results 2007-001029-84 A multicentre randomised, placebo-controlled, double-blind pivotal clinical trial for the evaluation of safety and efficacy of specific of immunotherapy with an aluminium hydroxide-adsorbed hypoallerg... 2011-05-31 due-trials
Reported results 2007-002808-18 A double-blind placebo controlled dose-response study for evaluation of safety and efficacy of immunotherapy with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense) ad... 2010-01-26 due-trials
Reported results 2007-003208-37 A multicentre multinational randomised, placebo-controlled, double-blind pivotal trial for the evaluation of safety and efficacy of specific immunotherapy with a cocktail of recombinant major allergen... 2012-03-29 due-trials
Reported results 2008-006258-16 A multicentre randomised placebo-controlled double-blind clinical trial for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hyp... 2011-04-26 due-trials
Reported results 2009-011504-36 Randomised double blind placebo controlled pivotal study to evaluate efficacy and safety of rPhleum in adult and adolescent patients suffering from rhinoconjunctivitis +/- controlled Asthma 2013-10-17 due-trials
Reported results 2009-014036-37 A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of a specific immunotherapy with an aluminium hydroxide adsorbed allergoid preparation of ... 2010-11-04 due-trials
Completed, but no date, and reported results 2011-000674-58 Double-blind, placebo controlled study to investigate the dose response of an allergoid preparation of Phleum pratense in adult patients with IgE mediated allergic Rhinitis / Rhinoconjunctivitis with ... bad-data
Reported results 2011-002248-29 A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of the optimal dose for safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allerg... 2015-05-21 due-trials
Reported results 2012-001914-41 Open label phase II multicentre clinical trial to evaluate safety during shortened uptitration of an allergoid grass pollen preparation in adult patients with IgE mediated allergic rhinitis / rhinocon... 2013-09-25 due-trials
Completed, but no date, and reported results 2013-003095-12 Double-blind phase IV multicentre clinical trial to evaluate and compare specific and non specific effects of SCIT by use of an Environmental Challenge Chamber after treatment with Allergovit® grasses... bad-data
Reported results 2015-000188-15 A multicenter randomized double-blind placebo-controlled clinical trial for evaluation of efficacy and safety of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of h... 2019-06-25 due-trials
Reported results 2015-002409-13 A multicenter, randomized, open-label clinical trial to evaluate safety and tolerability of a year-round initiation of specific immunotherapy with an aluminum hydroxide adsorbed allergoid preparation ... 2017-04-11 due-trials
Reported results 2015-005400-28 Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhinoco... 2017-03-30 due-trials
Reported results 2017-000754-19 A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxide a... 2018-07-03 due-trials
Reported results 2018-000548-25 A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxide a... 2019-07-22 due-trials
Reported results 2020-004328-41 A multicentre, randomized, open label clinical trial for the safety evaluation of a short dose escalation scheme using one strength for allergen immunotherapy with an aluminium-hydroxide adsorbed nati... 2022-07-14 due-trials
Reported results 2021-002317-34 A multicenter, randomized, open label clinical trial for safety evaluation of an allergen immunotherapy with an accelerated dose escalation schedule using one strength of an aluminium hydroxide adsorb... 2023-03-29 due-trials